infliximab
7 abstracts
Abstract
Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Germline variation and risk of immune-related adverse events (irAEs): A real-world BioVU study.Org: UCSF Hem/Onc Fellowship,
Abstract
Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The University of Texas Health Science Center at Houston,
Abstract
Effect of fecal transplantation on patients’ reported outcome after immune checkpoint inhibitor colitis.Org: MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Symptom Research, University of Texas at MD Anderson Cancer Center,
Abstract
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Management of immune related adverse events through electronic multidisciplinary consultation: Five years of experience from Peking Union Medical College Hospital.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, São Paulo, Brazil, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil, Beneficencia Portuguesa, AC Camargo Cancer Center,